Empagliflozin Attenuates Diabetic Cardiomyopathy via Inhibiting Cardiomyocyte Ferroptosis Through the USP7/NRF2 Signaling Pathway.

Empagliflozin 透過抑制 USP7/NRF2 訊息傳導路徑中的心肌細胞鐵死亡，減輕糖尿病性心肌病變